Common Contracts
6 similar Executive Employment Agreement contracts by Aimmune Therapeutics, Inc.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is effective as of January 22, 2019 (the “Effective Date”), by and between Andrew Oxtoby (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 8th, 2018 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is entered into as of 4th June, 2018 by and between Jayson Dallas, M.D. (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2017 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is effective as of April 28, 2017 (the “Effective Date”), by and between Eric Bjerkholt (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 10th, 2016 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is effective as of June 16, 2016 (the “Effective Date”), by and between Dan Adelman (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 16th, 2016 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is effective as of February 1, 2016 (the “Effective Date”), by and between Jeffrey Knapp (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 16th, 2016 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is effective as of April 4, 2016 (the “Effective Date”), by and between Doug Sheehy (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
